Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease
Sponsor: The Dana Foundation
Listed as NCT01409915, this PHASE2 trial focuses on Alzheimer's Disease and remains completed. Sponsored by The Dana Foundation, it has been updated 13 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Dana Foundation
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .